Login / Signup
Letter: distinct hepatitis B virus relapse rates after discontinuing tenofovir and entecavir therapy in chronic hepatitis B patients-author's reply.
Chien-Hung Chen
Published in:
Alimentary pharmacology & therapeutics (2020)
Keyphrases
</>
hepatitis b virus
end stage renal disease
ejection fraction
newly diagnosed
liver failure
chronic kidney disease
patient reported outcomes
stem cells
replacement therapy